White Paper AGA

Functional Dyspepsia

Nimish B. Vakil, Colin Howden, Paul Moayyedi, Jan Tack

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Functional dyspepsia remains a major challenge for clinicians with no approved drugs available in the Western World. In October 2016, a meeting was held in Washington, DC, sponsored by the American Gastroenterological Association's Center for Diagnostics and Therapeutics, which included members of the Food and Drug Administration (FDA) and the pharmaceutical industry, experts in FD, and representatives of patient organizations. This white paper summarizes our current status, progress with a validated patient reported outcome instrument in functional dyspepsia, future directions and needs.

Original languageEnglish (US)
Pages (from-to)1191-1194
Number of pages4
JournalClinical Gastroenterology and Hepatology
Volume15
Issue number8
DOIs
StatePublished - Aug 1 2017

Fingerprint

Dyspepsia
Patient Advocacy
Western World
Drug Industry
United States Food and Drug Administration
Organizations
Pharmaceutical Preparations
Therapeutics
Direction compound
Patient Reported Outcome Measures

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

White Paper AGA : Functional Dyspepsia. / Vakil, Nimish B.; Howden, Colin; Moayyedi, Paul; Tack, Jan.

In: Clinical Gastroenterology and Hepatology, Vol. 15, No. 8, 01.08.2017, p. 1191-1194.

Research output: Contribution to journalArticle

Vakil, Nimish B. ; Howden, Colin ; Moayyedi, Paul ; Tack, Jan. / White Paper AGA : Functional Dyspepsia. In: Clinical Gastroenterology and Hepatology. 2017 ; Vol. 15, No. 8. pp. 1191-1194.
@article{390c8a596ba74e8fb256d175a59934ae,
title = "White Paper AGA: Functional Dyspepsia",
abstract = "Functional dyspepsia remains a major challenge for clinicians with no approved drugs available in the Western World. In October 2016, a meeting was held in Washington, DC, sponsored by the American Gastroenterological Association's Center for Diagnostics and Therapeutics, which included members of the Food and Drug Administration (FDA) and the pharmaceutical industry, experts in FD, and representatives of patient organizations. This white paper summarizes our current status, progress with a validated patient reported outcome instrument in functional dyspepsia, future directions and needs.",
author = "Vakil, {Nimish B.} and Colin Howden and Paul Moayyedi and Jan Tack",
year = "2017",
month = "8",
day = "1",
doi = "10.1016/j.cgh.2017.05.013",
language = "English (US)",
volume = "15",
pages = "1191--1194",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "8",

}

TY - JOUR

T1 - White Paper AGA

T2 - Functional Dyspepsia

AU - Vakil, Nimish B.

AU - Howden, Colin

AU - Moayyedi, Paul

AU - Tack, Jan

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Functional dyspepsia remains a major challenge for clinicians with no approved drugs available in the Western World. In October 2016, a meeting was held in Washington, DC, sponsored by the American Gastroenterological Association's Center for Diagnostics and Therapeutics, which included members of the Food and Drug Administration (FDA) and the pharmaceutical industry, experts in FD, and representatives of patient organizations. This white paper summarizes our current status, progress with a validated patient reported outcome instrument in functional dyspepsia, future directions and needs.

AB - Functional dyspepsia remains a major challenge for clinicians with no approved drugs available in the Western World. In October 2016, a meeting was held in Washington, DC, sponsored by the American Gastroenterological Association's Center for Diagnostics and Therapeutics, which included members of the Food and Drug Administration (FDA) and the pharmaceutical industry, experts in FD, and representatives of patient organizations. This white paper summarizes our current status, progress with a validated patient reported outcome instrument in functional dyspepsia, future directions and needs.

UR - http://www.scopus.com/inward/record.url?scp=85024114515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024114515&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2017.05.013

DO - 10.1016/j.cgh.2017.05.013

M3 - Article

VL - 15

SP - 1191

EP - 1194

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 8

ER -